GSK_ Annual_Report_2021-22

VACCINES • Indicated for active booster immunisation against diphtheria, tetanus and pertussis in individuals aged 4+ years • Injectable suspension for intramuscular use • It is the only Tdap vaccine approved by the FDA for adults aged 65+ years and can be given to pregnant mothers also • Ranked No. 1 in the segment* • Boostrix is India’s first and trusted Tdap vaccine Boostrix • Indicated for active immunisation from age group of 6 months and older for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus lineages contained in the vaccine • For injection in intramuscular use • Ranked No. 2 in the segment* • World’s first inactivated quadrivalent influenza vaccines (QIV) which is manufactured in Germany • Over 24 crore doses sold worldwide • Indicated for active immunisation against varicella of healthy subjects • Powder and solvent for solution for injection to be given subcutaneously • Ranked No. 1 in the segment* • World’s first varicella vaccine with robust and proven efficacy data • Registered in over 90 countries, trusted worldwide with more than 30 years of experience Fluarix Tetra Varilrix SPECIALTY • First anti-IL5 drug in India • Indicated for adults suffering from severe eosinophilic asthma (SEA) • Launched Nucala auto-injector device for easier self-administration Nucala • First once-daily single-inhaler triple therapy (SITT) in India for the maintenance treatment of chronic obstructive pulmonary disease (COPD) patients Trelegy Ellipta *Source: IQVIA MAT March 2022 7 Financial Statements Statutory Reports Strategic Priorities Corporate Overview